• eIF4F, AKT1, and EZH2 in BRAF-Mutant Melanoma

  2026-09-10

  The reference study identifies coordinated ERK1/2–EZH2 and AKT1–eIF4E signaling as adaptive resistance mechanisms activated by eIF4F inhibition in BRAFV600E melanoma. Its combination experiments show that simultaneous targeting of eIF4F, EZH2, and AKT1 can improve suppression of sensitive and resistant melanoma models and restore response to BRAF inhibition.

• Streptavidin-FITC for LNP Tracking and Assays

  2026-09-09

  Streptavidin-FITC provides a practical fluorescent route for detecting biotinylated antibodies, nucleic acids, and nanoparticle-associated biomolecules across imaging and flow workflows. This guide connects assay design with recent LNP biology, showing how to distinguish particle localization from functional nucleic acid delivery.

• Macrophage EP4, CD36, and Atherosclerosis

  2026-09-09

  The reference study identifies macrophage EP4 loss as a driver of atherosclerosis progression, linking increased CD36 expression with foam cell formation and M1 polarization. Its combination of a myeloid-specific knockout model, oxLDL-stimulated macrophages, transcriptomics, proteomics, qPCR, and Western blotting provides a mechanistic framework for interpreting how lipid uptake and inflammation interact in plaques.

• Direct Mouse Genotyping Kit Plus: Mechanistic QC

  2026-09-08

  The Direct Mouse Genotyping Kit Plus can strengthen the genotype-to-phenotype audit trail in macrophage EP4 mouse models. This article connects rapid DNA preparation and high-fidelity PCR with assay decisions for transgene detection, gene knockout validation, and cardiovascular research reproducibility.

• Pexidartinib and the CSF1R Logic of Cell State

  2026-09-08

  Pexidartinib (PLX3397) offers a receptor-directed way to interrogate macrophage and microglial biology. This thought-leadership analysis connects CSF1R-mediated signaling inhibition in oncology with emerging evidence that microglial activation reshapes hippocampal synaptic balance, while defining the experimental safeguards needed for responsible translational interpretation.

• Calcitriol and NFIA: A New Lens on Bone Homeostasis

  2026-09-07

  A translational framework linking Calcitriol biology with NFIA-regulated bone remodeling, immune signaling, experimental design, and program strategy.

• HDAC Inhibitors Repress NUT Carcinoma Programs

  2026-09-07

  Shiota and colleagues developed a dCas9-based GFP reporter screen to identify compounds that suppress NUT-driven transcription, uncovering structurally diverse HDAC inhibitors as potent repressors of the NUT carcinoma program. Panobinostat and IRBM6 reduced megadomain-associated oncogenic transcription, promoted differentiation, and constrained tumor growth, providing a mechanistic rationale for combining chromatin-directed therapies.

• TNF-alpha Recombinant Murine Protein Workflow

  2026-09-05

  Build reproducible apoptosis and inflammation assays with a defined, trimeric murine cytokine rather than relying on poorly characterized conditioned media. This workflow uses TNF-alpha as a receptor-initiated benchmark alongside RNA Pol II degradation studies, helping separate inflammatory signaling from transcription-independent cell death.

• Luminescent ATP Cell Viability Assay Kit I

  2026-09-04

  This scenario-based guide explains how Luminescent ATP Cell Viability Assay Kit I (SKU K2041) supports sensitive cell viability measurement, cytotoxicity testing, and proliferation studies. It covers assay principles, experimental design, protocol parameters, interpretation limits, and practical vendor-selection considerations for reproducible laboratory workflows.

• Hoe 140: Potent Bradykinin Antagonism In Vitro

  2026-09-04

  Hock and colleagues characterized Hoe 140 as a structurally distinctive, highly potent bradykinin antagonist using receptor-binding, isolated-organ, and endothelial-cell assays. The study established a major potency advance over an earlier peptide antagonist while also showing inhibition of bradykinin-dependent vascular signaling, providing a foundation for later bradykinin-pathway pharmacology.

• Amikacin Sulfate: From Mechanism to Translation

  2026-09-03

  Amikacin Sulfate is more than a conventional aminoglycoside benchmark. Its value in non-tuberculous mycobacterial research lies in connecting 30S ribosomal targeting with intracellular exposure, granulomatous tissue distribution, and delivery-led improvements in therapeutic index. This article outlines a translational framework for validating Amikacin across cellular, animal, and next-generation formulation studies.

• Gastrodin, AT1 Signaling, and Reactive Astrocytes

  2026-09-03

  A 2024 European Journal of Neuroscience study used a microglia-conditioned medium model to show that gastrodin reshapes renin–angiotensin system, SIRT3, inflammatory, and neurotrophic responses in reactive astrocytes. Pharmacological AT1 inhibition supported a role for AT1 signaling in astrocyte phenotype regulation, while the cellular design also defines important limits for translation to brain disease models.

• S-Nitrosylation Coordinates Aluminum Resistance

  2026-09-02

  A 2026 Molecular Plant study identifies nitric oxide-dependent S-nitrosylation as a mechanism that differentially regulates STOP1 and STAR1 in Arabidopsis. The findings connect STOP1-driven external aluminum exclusion with STAR1/ALS3-mediated internal sequestration and provide a framework for testing redox-sensitive cysteine regulation using reversible thiol labeling.

• Amikacin Sulfate: From Intracellular Killing to Delivery

  2026-09-02

  Amikacin Sulfate is more than a conventional aminoglycoside assay reagent: it is a translational probe for understanding how antibacterial activity, intracellular exposure, tissue targeting, and microbiome-aware discovery intersect. This article outlines a practical framework for moving from 30S ribosome mechanism to reproducible NTM models and delivery strategies.

• FUS–SMN Phase Separation in Neuronal Granules

  2026-09-01

  Wang and Li show that asymmetric arginine dimethylation enables FUS to engage oligomeric SMN through multivalent Tudor-domain interactions, promoting phase separation and neuronal granule formation. Their rescue experiments connect this molecular mechanism to axonal mRNA distribution, axon growth, and neuronal function, while highlighting SMN valency as a disease-relevant variable in spinal muscular atrophy.

8001 records 1/534 page Next 12345 下5页 Last page